An announcement from Knight Therapeutics ( (TSE:GUD) ) is now available.
Knight Therapeutics reported record-high revenues for the fourth quarter and year-end 2024, with a 13% increase driven by the growth of key promoted products and the impact of hyperinflation in Argentina. The company achieved significant corporate developments, including launching a Normal Course Issuer Bid (NCIB) and obtaining regulatory approvals for several products in Latin America and Canada, which strengthens its market position and product portfolio.
More about Knight Therapeutics
Knight Therapeutics Inc. is a pan-American specialty pharmaceutical company focused on developing and commercializing pharmaceutical products in Canada and Latin America, excluding the United States.
YTD Price Performance: 16.76%
Average Trading Volume: 1,715
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $429.7M
See more data about GUD stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com